Our CEO and founder, Matt Cantelo recently sat down with leading business publication, My Business to discuss the future of the Australian medicinal cannabis industry, ANTG’s plans for growth, the role of the industry to facilitate greater research and ANTG’s exciting partnership with Cannamedical Pharma to export Australian grown cannabis to the expanding German market. Read the article here.
ANTG has listed two new THC-dominant medicinal cannabis strains on the Australian Register of Therapeutic Goods (ARTG).
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.LEARN ABOUT ANTG HERE >